Screening and discovery of nitro-benzoxadiazole compounds activating epidermal growth factor receptor (EGFR) in cancer cells

Sci Rep. 2014 Feb 5:4:3977. doi: 10.1038/srep03977.

Abstract

Peptide ligand-induced dimerization of the extracellular region of the epidermal growth factor receptor (sEGFR) is central to the signal transduction of many cellular processes. A small molecule microarray screen has been developed to search for non-peptide compounds able to bind to sEGFR. We describe the discovery of nitro-benzoxadiazole (NBD) compounds that enhance tyrosine phosphorylation of EGFR and thereby trigger downstream signaling pathways and other receptor tyrosine kinases in cancer cells. The protein phosphorylation profile in cells exposed to NBD compounds is to some extent reminiscent of the profile induced by the cognate ligand. Experimental studies indicate that the small compounds bind to the dimerization domain of sEGFR, and generate stable dimers providing allosteric activation of the receptor. Moreover, receptor phosphorylation is associated with inhibition of PTP-1B phosphatase. Our data offer a promising paradigm for investigating new aspects of signal transduction mediated by EGFR in cancer cells exposed to electrophilic NBD compounds.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Enzyme Activation / drug effects*
  • Enzyme Inhibitors / pharmacology
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / metabolism*
  • Humans
  • Neoplasms / pathology*
  • Nitro Compounds / pharmacology*
  • Oxadiazoles / pharmacology*
  • Phosphorylation / drug effects
  • Quinazolines / pharmacology
  • Signal Transduction / drug effects
  • Tyrphostins / pharmacology

Substances

  • Enzyme Inhibitors
  • Nitro Compounds
  • Oxadiazoles
  • Quinazolines
  • Tyrphostins
  • RTKI cpd
  • EGFR protein, human
  • ErbB Receptors
  • 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline